JIA Trial: Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment
Principal Investigator: Dr. Lily Lim
Juvenile Idiopathic Arthritis (JIA) is the most common pediatric rheumatic disease in North America. Treatment of JIA has been revolutionized by using portions of the body’s natural immune system to treat the disease, but not everyone responds the same. This trial aims to figure out why people respond differently and how to predict different responses. Ultimately, this will help healthcare providers provide personalized care to children with JIA.